https://www.yiliao.com/index.php?action=history&feed=atom&title=BEACON%E6%96%B9%E6%A1%88
BEACON方案 - 版本历史
2026-04-09T23:01:47Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=BEACON%E6%96%B9%E6%A1%88&diff=316432&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-02-04T13:14:05Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>BEACON方案</strong>（BEACON Regimen）是针对携带 <strong>BRAF V600E</strong> 突变的转移性结直肠癌（mCRC）的一种突破性<strong>无化疗 (Chemotherapy-free)</strong> 靶向联合治疗方案。<br />
<br>该方案基于里程碑式的 III 期临床试验 <strong>BEACON CRC</strong> 的结果，确立了以 <strong>[[恩考芬尼]]</strong> (Encorafenib, BRAF抑制剂) 联合 <strong>[[西妥昔单抗]]</strong> (Cetuximab, EGFR抑制剂) 的双药联合方案（Doublet）作为该类患者的标准二线治疗（SOC）。BEACON 研究证明，通过垂直阻断 <strong>[[MAPK信号通路]]</strong>，可以显著延长患者的总生存期（OS），打破了 BRAF V600E 突变结直肠癌预后极差的魔咒。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">BEACON Regimen</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">BEACON CRC Study (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="width: 100px; height: 100px; background-color: #e2e8f0; border-radius: 50%; margin: 0 auto; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em;"><br />
<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">CRC 靶向治疗里程碑</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">方案概况</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">适应症</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">mCRC (BRAF V600E+)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">核心药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[Encorafenib]] + [[Cetuximab]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">治疗线数</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">二线及以上 (2L+)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">ORR (双药)</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;">~20% (vs 对照组 2%)</td><br />
</tr><br />
<br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">指南推荐</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">NCCN</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">Category 1 (首选)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">CSCO</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">I 级推荐</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">发表年份</th><br />
<td style="padding: 6px 12px; color: #0f172a;">2019 (NEJM)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心原理：垂直阻断与反馈抑制</h2><br />
<br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
为什么在黑色素瘤中单用 BRAF 抑制剂有效，而在结直肠癌中无效？答案在于“反馈通路”。<br />
</p><br />
<br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>结直肠癌的特殊性：</strong> 当 BRAF V600E 被抑制时，结直肠癌细胞会通过负反馈机制，迅速上调上游 <strong>[[EGFR]]</strong> 的活性，绕过 BRAF 继续激活下游的 MAPK 通路，导致单药耐药。</li><br />
<li style="margin-bottom: 12px;"><strong>垂直阻断策略 (Vertical Blockade)：</strong> BEACON 方案同时使用了 BRAF 抑制剂（恩考芬尼）和 EGFR 单抗（西妥昔单抗），像“两头堵”一样，同时切断了驱动信号和反馈信号，实现了对癌细胞的强效抑制。</li><br />
<li style="margin-bottom: 0;"><strong>三药 vs 双药：</strong> 最初的试验还包含了 MEK 抑制剂（比美替尼）作为三药联合（Triplet）。但后续分析发现，<strong>双药联合（Doublet）</strong> 在生存获益上与三药相当，且毒副作用更低。因此，目前的指南更推荐双药方案。</li><br />
</ul><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">循证医学：BEACON CRC 试验数据</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
BEACON CRC 是首个专门针对 BRAF V600E 突变 mCRC 的大型 III 期随机对照试验。<br />
</p><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">组别</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 25%;">中位 OS</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 20%;">ORR (缓解率)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #16a34a; width: 30%;">结论</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">三药组 (Triplet)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">9.3 个月</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">26.8%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">疗效好，但 3 级以上不良反应稍高 (58%)。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #1e40af;">双药组 (Doublet)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;"><strong>9.3 个月</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>19.5%</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>性价比之王</strong>。生存期与三药一致，副作用更少 (50%)。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #64748b;">对照组 (化疗)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">5.9 个月</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">1.8%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">传统的 FOLFIRI/伊立替康 + 西妥昔单抗效果极差。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床意义与应用</h2><br />
<br />
<ul style="padding-left: 25px; color: #334155; margin-top: 15px;"><br />
<li style="margin-bottom: 12px;"><strong>改写指南：</strong> 基于此研究，NCCN 指南将“恩考芬尼 + 西妥昔单抗”列为 BRAF V600E 突变 mCRC 二线治疗的 <strong>Category 1</strong> 推荐，并指出对于体能状态好的患者，甚至可考虑一线应用（ANCHOR CRC 研究支持）。</li><br />
<li style="margin-bottom: 12px;"><strong>去化疗化：</strong> 这是结直肠癌领域罕见的无需细胞毒性化疗药物（如氟尿嘧啶、奥沙利铂）即可获得生存获益的方案，显著提高了患者的生活质量。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Kopetz S, et al. (2019).</strong> <em>Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>. <br><br />
<span style="color: #475569;">[点评]：BEACON CRC 的主要论文。确立了靶向联合治疗优于标准护理（化疗）的地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Tabernero J, et al. (2021).</strong> <em>Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutated Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON CRC Study.</em> <strong>[[Journal of Clinical Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：更新的数据分析。明确了“双药”与“三药”在 OS 上没有显著差异，从而确立了双药方案作为首选标准。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Van Cutsem E, et al. (2021).</strong> <em>ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer.</em> <strong>[[Annals of Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：探索了该方案在一线治疗中的潜力，显示出高缓解率（47.8%）。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
结直肠癌治疗 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">上级分类</td><br />
<td style="padding: 10px 15px; color: #334155;">[[结直肠癌]] • 靶向治疗方案</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心组分</td><br />
<td style="padding: 10px 15px; color: #334155;">[[恩考芬尼]] (BRAFi) • [[西妥昔单抗]] (EGFRi)</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">对比方案</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FOLFIRI]] • [[VIC方案]] (维莫非尼组合)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020